SUPERNUS PHARMACEUTICALS, INC. Insurance Recoveries
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Insurance Recoveries of $2.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InsuranceRecoveries · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for the quarter ending 2026-06-30 was $2.40M, a 140.00% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for the quarter ending 2026-03-31 was $1.50M, a 65.91% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for the quarter ending 2025-12-31 was $4.10M, a 86.36% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for the quarter ending 2025-09-30 was $800.00K, a 93.04% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for fiscal 2025 was $10.30M, a 27.46% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for fiscal 2024 was $14.20M.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for fiscal 2023 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. insurance recoveries for fiscal 2022 was $0.00.
| Period end | Insurance Recoveries 3 month | Insurance Recoveries 6 month | Insurance Recoveries 9 month | Insurance Recoveries 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.40M 10-Q · filed 2026-08-03 | $3.90M 10-Q · filed 2026-08-03 | $8.00M derived: sum of 3 quarters · filed 2026-08-03 | $8.80M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-05 | $5.60M derived: sum of 2 quarters · filed 2026-05-05 | $6.40M derived: sum of 3 quarters · filed 2026-05-05 | $7.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.90M derived: sum of 2 quarters · filed 2026-03-02 | $5.90M derived: sum of 3 quarters · filed 2026-08-03 | $10.30M 10-K · filed 2026-03-02 |
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-06 | $1.80M derived: sum of 2 quarters · filed 2026-08-03 | $6.20M 10-Q · filed 2025-11-06 | $8.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-03 | $5.40M 10-Q · filed 2026-08-03 | $7.60M derived: sum of 3 quarters · filed 2026-08-03 | $19.10M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $4.40M 10-Q · filed 2026-05-05 | $6.60M derived: sum of 2 quarters · filed 2026-05-05 | $18.10M derived: sum of 3 quarters · filed 2026-05-05 | $18.10M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.70M derived: sum of 2 quarters · filed 2026-03-02 | $13.70M derived: sum of 3 quarters · filed 2026-03-02 | $14.20M 10-K · filed 2026-03-02 |
| 2024-09-30 | $11.50M 10-Q · filed 2025-11-06 | $11.50M derived: sum of 2 quarters · filed 2025-11-06 | $12.00M 10-Q · filed 2025-11-06 | $11.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |